Lacosamide Teva (Lacosamide)

Lacosamide selectively enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. By stabilising hyper‑excitable neurons, it limits the repetitive firing that underlies seizure activity, thereby contributing to overall seizure control without markedly affecting normal brain function.

The specific dose of Lacosamide Teva is determined by the prescribing clinician based on the patient’s age, weight, renal function, and response to therapy. Dosage titration follows established clinical guidelines, and patients should follow the prescriber’s instructions precisely.

Safety data for lacosamide in pregnancy and lactation are limited. The medication should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lacosamide’s unique mechanism—enhancing slow sodium‑channel inactivation—differs from many traditional antiepileptics that block fast sodium channels. This can provide additive seizure control when combined with other agents and may be better tolerated in some patients, though individual response varies and should be assessed by a neurologist.

Lacosamide Teva is administered orally, usually as a tablet taken with or without food. The prescriber will advise the exact dosing schedule, which often starts with a low dose and is gradually increased to achieve optimal seizure control while monitoring for side effects.

Serious adverse events include cardiac conduction abnormalities such as PR‑interval prolongation, severe skin reactions like Stevens‑Johnson syndrome, suicidal thoughts or behaviours, and significant hepatic dysfunction. Patients should seek immediate medical attention if they experience palpitations, rash, mood changes, or jaundice.

Lacosamide Teva is contraindicated in individuals with known hypersensitivity to lacosamide or any of its excipients. Caution is advised for patients with severe cardiac conduction disorders, significant hepatic impairment, or those taking other medications that markedly prolong the PR interval. Pregnant or breastfeeding women should only use it under strict medical supervision.